NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 – 18, 2022.
| 11th Annual SVB Leerink Global Healthcare Conference | |||
| Date: | Wednesday, February 16th, 2022 | ||
| Time: | 11:20am Eastern Time | ||
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com | ||
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing batoclimab, formerly referred to as IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a…
KENNEWICK, Wash. and HOUSTON, Dec. 11, 2025 /PRNewswire/ -- Cadwell, a global leader in neurodiagnostic…
New embedded solution empowers more than 900,000 small businesses to offer flexible, affordable health coverage directly…
CONSHOHOCKEN, Pa., Dec. 11, 2025 /PRNewswire/ -- Suvoda, a global clinical trial technology company, today announced…
TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving…
VISALIA, Calif., Dec. 11, 2025 /PRNewswire/ -- Maison Law Accident & Injury Lawyers announces the…